Patients with PD-L1 expression by IHC 1/2/3 demonstrated evidence of increased activity. Durable responses were observed in mRCC patients, warranting further study Randomized, dose-ranging phase II trial of nivolumab for metastatic renal cell carcinoma (mRCC) Meeting Abstract
| Authors: | Motzer, R.; Rini, B.; McDermott, D.; Redman, B.; Kuzel, T.; Harrison, M.; Vaishampayan, U.; Drabkin, H.; George, S.; Logan, T.; Margolin, K.; Plimack, E. R.; Waxman, I.; Lambert, A.; Hammers, H. |
| Abstract Title: | Patients with PD-L1 expression by IHC 1/2/3 demonstrated evidence of increased activity. Durable responses were observed in mRCC patients, warranting further study Randomized, dose-ranging phase II trial of nivolumab for metastatic renal cell carcinoma (mRCC) |
| Meeting Title: | 13th International Kidney Cancer Symposium |
| Journal Title: | BJU International |
| Volume: | 114 |
| Issue: | Suppl. S4 |
| Meeting Dates: | 2014 OCT 24-25 |
| Meeting Location: | Chicago, IL |
| ISSN: | 1464-4096 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2014-10-01 |
| Start Page: | 12 |
| End Page: | 12 |
| Language: | English |
| ACCESSION: | WOS:000344393900021 |
| PROVIDER: | wos |
| DOI: | 10.1111/bju.12941 |
| Notes: | Meeting Abstract -- 13th International Kidney Cancer Symposium -- OCT 24-25, 2014 -- Chicago, IL -- 4 -- SI -- Source: Wos |
